Physician profile
Andrew E Segraves
NPI 1487997110
$19,409.95
in general payments reported to CMS, 2019-2025
35 companies · $3,139 in 2025
The $3,139 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,365 · 2020: $1,589 · 2021: $2,954 · 2022: $2,759 · 2023: $3,579 · 2024: $3,025 · 2025: $3,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,718 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,717.66 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,359.82 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,961.97 | 2021-2025 | Vraylar, Qulipta |
| Lundbeck LLC | $1,661.66 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,563.73 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,083.13 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $992.66 | 2019-2025 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $868.02 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $847.59 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $829.14 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Corium, LLC | $817.76 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $621.80 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $602.88 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $586.05 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $540.87 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $474.23 | 2019-2023 | Adzenys Xr-Odt |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $454.70 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $398.28 | 2019-2022 | |
| Alkermes, INC. | $392.82 | 2021-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $354.84 | 2019-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $296.23 | 2024-2025 | Cobenfy |
| Eisai INC. | $260.69 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $197.93 | 2019-2022 | |
| Biogen, INC. | $196.73 | 2020-2024 | |
| Almatica Pharma LLC | $167.62 | 2021-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $159.66 | 2020-2023 | Belsomra |
| Acadia Pharmaceuticals INC | $142.18 | 2021-2025 | Nuplazid |
| Shire North American Group INC | $112.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $104.90 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $88.54 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $85.24 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $60.88 | 2022-2024 | Quviviq |
| Adlon Therapeutics L.P. | $54.37 | 2020-2021 | |
| Alfasigma USA, INC. | $38.64 | 2021-2022 | |
| Noven Therapeutics, LLC | $16.20 | 2024 | Xelstrym |
| Amgen INC. | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Segraves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.